Abstract:Abstract Introduction: Young women with estrogen receptor (ER)-positive early-stage breast cancer (EBC) frequently present with larger, higher-grade, more aggressive tumors, with lower ER expression than older women. Post-hoc analyses within the MINDACT and TAILORx cohorts reported that women aged 40-50 with ER+ EBC exhibited a chemotherapy benefit independent of genomic risk compared to women aged > 50, possibly due to chemotherapy-induced ovarian suppression (CIOS). However, women < 40 years, who seldom develop CIOS, are under-represented in clinical trials. Therefore, it is important to distinguish the tumor biological profile within this younger age group. To understand the biological basis underlying why younger women have poorer outcomes than older women, this study aimed to identify genes that distinguish tumors in younger women from older women. Methods: EBC patients enrolled in the FLEX study (NCT03053193) undergo standard of care MammaPrint (MP) and BluePrint (BP) tests, and consent to clinically annotated whole transcriptome data collection. MP categorizes tumors as High Risk (HR) or Low Risk (LR) of recurrence. Together, MP and BP classify molecular subtype as Luminal A, Luminal B, HER2, or Basal. Whole transcriptome gene expression differences were compared among ER+ tumor specimens from three age groups: < 40 years old (n=283), 40-54 years old (n=1535), and ≥ 55 years old (n=4355). Differentially expressed genes (DEGs) were identified from 100 randomized iterations for each comparison; an equal number of LR and HR samples were analyzed in each group. DEGs found in > 20 iterations indicated gene stability within the age group. DEGs were also identified within each age group after correcting for BP subtype, and between pre-menopausal (n=1314) and post-menopausal (n=4859) women. Gene expression data were quantile normalized using R package ‘limma’. DEGs with an adjusted p<0.05 and fold change ≥ 2 were considered significant. Results: Overall, 76.0% of women < 40 years, 53.6% of women aged 40-54, and 48.5% of women ≥ 55 years had MP HR tumors. In addition, women < 40 years had higher frequencies of BP Basal and HER2 tumors (20.5% and 9.2%, respectively) compared with women ≥ 55 years (8.0% and 2.4%, respectively; p<0.0001). In line with unsupervised hierarchical clustering and previous studies, tumors from patients aged 40-54 exhibited limited DEGs in comparison to women ≥ 55 years. In contrast, most gene expression differences were primarily observed between women < 40 and ≥ 55 years (11 DEGs; 10 downregulated and 1 upregulated). We identified limited DEGs within BP Luminal A (n=23), Luminal B (n=10), and Basal (n=7) tumors from women aged < 40 relative to women ≥ 55 years. No DEGs were found in HER2-type tumors. Within Luminal A and Basal tumors, upregulated genes in women < 40 years are important for proliferation and immune responses. Luminal B tumors in women aged < 40 have increased DEGs involved in ER and HER2 signaling. Within all subtypes, DEGs supporting metabolic functions were downregulated in tumors of women < 40 years compared with women ≥ 55 years. Few DEGs were observed between pre-menopausal women and post-menopausal women, though none with > 2-fold change. Conclusion: Tumors from women aged 40-54 had few DEGs, suggesting observed chemotherapy benefit represents differences in host biology rather than intrinsic tumor biology as compared with tumors from women < 40 or ≥ 55, where detected DEGs are associated with proliferation, receptor signaling, and metabolism. Fewer DEGs were observed by menopausal status than age, indicating age is a more relevant cutoff. Future studies will aim to further characterize this high risk young patient population. Citation Format: Shubhada Dhage, Mina Gendy, Nina D'Abreo, Ruth Oratz, Sami G. Diab, VK Gadi, Cathy Graham, Midas Kuilman, Shiyu Wang, Patricia Dauer, Andrea Menicucci, William Audeh, Douglas K. Marks. Deciphering the inferior prognosis of young women with estrogen receptor-positive early-stage breast cancer through full transcriptome analysis: A FLEX database sub-study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-07-05.

Sex-based differences in the transcriptomic metabolic profiling in young onset colorectal cancer (YOCRC).

Impact of Sex Differences on Cross- Talk Between the Gut Microbiome, CEACAMs, and TGF-β Signaling in Cancers

Abstract 250: Sex differences in cancer stemness among individuals with early onset colorectal cancer

Immune Microenvironment in Sporadic Early-Onset versus Average-Onset Colorectal Cancer

Identification of differentially expressed genes and splicing events in early-onset colorectal cancer

Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in patients (pts) with metastatic colorectal cancer (mCRC).

Single-Cell RNA Sequencing Reveals Heterogeneity in the Tumor Microenvironment between Young-Onset and Old-Onset Colorectal Cancer

X or Y Cancer: An Extensive Analysis of Sex Differences in Lung Adenocarcinoma

Gene regulatory network analysis identifies sex-linked differences in colon cancer drug metabolism processes

Molecular differences with therapeutic implications in early-onset compared to average-onset cholangiocarcinoma.

Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer

Metabolic Dysregulation Explains the Diverse Impacts of Obesity in Males and Females with Gastrointestinal Cancers

Transcriptomic landscape of early age onset of colorectal cancer identifies novel genes and pathways in Indian CRC patients

Comprehensive study of the intratumoral microbiome in early- vs. late-onset colorectal cancer: Final analysis of COSMO CRC.

IDDF2024-ABS-0170 Metagenomic Analyses Highlight Strain-Level, Age-Independent and Immunotherapy-Associated Microbial Signatures in Colorectal Cancer

Distinct Plasma Molecular Profiles Between Early-onset and Late-onset Colorectal Cancer Patients Revealed by Metabolic and Lipidomic Analyses

Abstract P5-07-05: Deciphering the inferior prognosis of young women with estrogen receptor-positive early-stage breast cancer through full transcriptome analysis: A FLEX database sub-study

Sex differences in survival outcomes of early-onset colorectal cancer

Plasma metabolomic differences in early-onset compared to average-onset colorectal cancer

Abstract 7005: Distinct DNA methylation patterns between early-onset and average-onset colorectal cancer patients

Distinct intratumoral microbiome of young-onset and average-onset colorectal cancer